Logo image of ADGI

ADAGIO THERAPEUTICS INC (ADGI) Stock Fundamental Analysis

USA - NASDAQ:ADGI - US00534A1025 - Common Stock

4.64 USD
+0.04 (+0.87%)
Last: 9/12/2022, 8:13:11 PM
4.52 USD
-0.12 (-2.59%)
After Hours: 9/12/2022, 8:13:11 PM
Fundamental Rating

2

ADGI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. ADGI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ADGI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ADGI had negative earnings in the past year.
ADGI Yearly Net Income VS EBIT VS OCF VS FCFADGI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 -50M -100M -150M -200M

1.2 Ratios

Industry RankSector Rank
ROA -60.89%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADGI Yearly ROA, ROE, ROICADGI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 -20 -40 -60

1.3 Margins

ADGI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADGI Yearly Profit, Operating, Gross MarginsADGI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021

More info and screens

6

2. Health

2.1 Basic Checks

ADGI has more shares outstanding than it did 1 year ago.
There is no outstanding debt for ADGI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ADGI Yearly Shares OutstandingADGI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 20M 40M 60M 80M 100M
ADGI Yearly Total Debt VS Total AssetsADGI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 200M 400M 600M

2.2 Solvency

ADGI has an Altman-Z score of 2.06. This is not the best score and indicates that ADGI is in the grey zone with still only limited risk for bankruptcy at the moment.
ADGI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.06
ROIC/WACCN/A
WACCN/A
ADGI Yearly LT Debt VS Equity VS FCFADGI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 0 200M 400M

2.3 Liquidity

ADGI has a Current Ratio of 7.09. This indicates that ADGI is financially healthy and has no problem in meeting its short term obligations.
ADGI has a Quick Ratio of 7.09. This indicates that ADGI is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 7.09
Quick Ratio 7.09
ADGI Yearly Current Assets VS Current LiabilitesADGI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 200M 400M 600M

More info and screens

0

3. Growth

3.1 Past

ADGI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -74.66%.
EPS 1Y (TTM)-74.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ADGI is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.19% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2.35%
EPS Next 2Y7.44%
EPS Next 3Y12.17%
EPS Next 5Y2.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADGI Yearly Revenue VS EstimatesADGI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 200M 400M 600M 800M
ADGI Yearly EPS VS EstimatesADGI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADGI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ADGI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADGI Price Earnings VS Forward Price EarningsADGI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADGI Per share dataADGI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ADGI's earnings are expected to grow with 12.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.44%
EPS Next 3Y12.17%

More info and screens

0

5. Dividend

5.1 Amount

ADGI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAGIO THERAPEUTICS INC

NASDAQ:ADGI (9/12/2022, 8:13:11 PM)

After market: 4.52 -0.12 (-2.59%)

4.64

+0.04 (+0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-15 2022-08-15/bmo
Earnings (Next)N/A N/A
Inst Owners65.86%
Inst Owner Change145.96%
Ins Owners12.29%
Ins Owner Change0%
Market Cap504.74M
Revenue(TTM)N/A
Net Income(TTM)-295.07M
Analysts46.67
Price Target3.91 (-15.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.22
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.15
EYN/A
EPS(NY)-2.02
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS3.81
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -60.89%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.09
Quick Ratio 7.09
Altman-Z 2.06
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.11%
EPS Next Y-2.35%
EPS Next 2Y7.44%
EPS Next 3Y12.17%
EPS Next 5Y2.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

ADAGIO THERAPEUTICS INC / ADGI FAQ

Can you provide the ChartMill fundamental rating for ADAGIO THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to ADGI.


Can you provide the valuation status for ADAGIO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to ADAGIO THERAPEUTICS INC (ADGI). This can be considered as Overvalued.


Can you provide the profitability details for ADAGIO THERAPEUTICS INC?

ADAGIO THERAPEUTICS INC (ADGI) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ADAGIO THERAPEUTICS INC?

The Earnings per Share (EPS) of ADAGIO THERAPEUTICS INC (ADGI) is expected to decline by -2.35% in the next year.